Core Insights - electroCore, Inc. has announced a new research initiative in collaboration with Acacia Clinics and the Vagus Nerve Society to investigate the use of gammaCore™ Sapphire, a non-invasive vagus nerve stimulator (nVNS), as an adjunctive treatment for PTSD symptoms [1][2] Study Details - The study titled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder" will be led by Danielle DeSouza MSc, PhD, and aims to assess the safety and effectiveness of gammaCore Sapphire [2] - The primary safety measure will focus on significant adverse events (SAEs) related to nVNS treatment, while the primary efficacy outcome will be the change in the Clinician-Administered PTSD Scale (CAPS-5) total score after a 12-week treatment period [2] - The study will enroll up to 40 subjects aged 18 to 70 diagnosed with PTSD and is expected to last for 10 months [3] Background Information - Acacia Clinics is recognized for its expertise in precision neuromodulation and advanced mental health services, founded in 2018 by Dr. David Carreon and Dr. Nathan Meng [4] - electroCore, Inc. focuses on improving health through innovative non-invasive bioelectronic technologies, with products like gammaCore® and Quell® targeting chronic pain syndromes [5]

Core Insights - electroCore, Inc. anticipates record revenue for full year 2025 of approximately $31.8 - $32.0 million, representing a growth of about 26% compared to 2024 revenue of $25.2 million [2][7] - For the fourth quarter of 2025, the company expects revenue to be approximately $9.0 - $9.2 million, indicating a growth of around 30% over the fourth quarter of 2024 [2][7] - The company's total cash position at the end of 2025 is approximately $11.6 million, down from approximately $13.2 million as of September 30, 2025 [3][7] Financial Guidance - Full year 2025 revenue is projected to be between $31.8 million and $32.0 million, marking a 26% increase from 2024 [2][7] - Fourth quarter 2025 revenue is expected to be between $9.0 million and $9.2 million, reflecting a 30% increase from the same quarter in 2024 [2][7] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [4] - The company's leading products include gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, which address chronic pain syndromes [4]

Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [3] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, and Quell neurostimulator, both aimed at treating chronic pain syndromes through non-invasive neuromodulation technology [3] - Additionally, electroCore offers handheld and personal use products such as Truvaga and TAC-STIM nVNS, which utilize bioelectronic technologies to promote general wellness and human performance [3] Upcoming Events - Management of electroCore will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at the Lotte New York Palace Hotel [1] - One-on-one meetings will be hosted throughout the day for interested investors [1] Investor Relations - Investors wishing to request a meeting can contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations via email at ecor@fnkir.com [2]